[caption id="attachment_9277" align="alignleft" width="1079"] Press Release[/caption] Oxford, UK:?Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymised patient data with anonymised electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed. The planned collaboration will be Sensyne Health?s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.

LORD (PAUL) DRAYSON PHD, CEO OF SENSYNE HEALTH PLC, SAID:

?This is an important collaboration and marks Sensyne?s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform. It is particularly pleasing given Roche?s progressive approach to data and technology-driven personalised healthcare.?